NYSEAMERICAN:NAVBNavidea Biopharmaceuticals Stock Price, Forecast & News

$2.57

+0.13 (+5.33 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$2.35

Now: $2.57▼

$2.69

50-Day Range N/A

52-Week Range

$0.49

Now: $2.57▼

$3.50

Volume1.57 million shs

Average Volume1.04 million shs

Market Capitalization$55.63 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Navidea Biopharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Navidea Biopharmaceuticals has a potential upside of 94.6% from its current price of $2.57.
Amount of Analyst Coverage
Navidea Biopharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Navidea Biopharmaceuticals has received 181 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Navidea Biopharmaceuticals has received 162 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Navidea Biopharmaceuticals has received 52.77% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote “Outperform” if you believe NAVB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NAVB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Navidea Biopharmaceuticals does not currently pay a dividend.
Dividend Growth
Navidea Biopharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Navidea Biopharmaceuticals insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

1.22 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN

Industry Biotechnology

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNYSEAMERICAN:NAVB

Previous SymbolNYSEMKT:NAVB

CUSIP63937X10

CIK810509

Webwww.navidea.com

Phone+1-614-7937500

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees14

Outstanding Shares21,645,000

Market Cap$55.63 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive NAVB News and Ratings via Email

Sign-up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Navidea Biopharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Navidea Biopharmaceuticals.

When is Navidea Biopharmaceuticals' next earnings date?

Navidea Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Navidea Biopharmaceuticals.

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) posted its quarterly earnings results on Wednesday, March, 11th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.03. The biopharmaceutical company earned $0.12 million during the quarter, compared to analysts' expectations of $0.30 million. View Navidea Biopharmaceuticals' earnings history.

What price target have analysts set for NAVB?

2 analysts have issued twelve-month price targets for Navidea Biopharmaceuticals' stock. Their forecasts range from $4.00 to $6.00. On average, they anticipate Navidea Biopharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 94.6% from the stock's current price. View analysts' price targets for Navidea Biopharmaceuticals.

What are Wall Street analysts saying about Navidea Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Navidea Biopharmaceuticals stock:

1. According to Zacks Investment Research, "Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company's radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and RIGScan(TM). Navidea Biopharmaceuticals, Inc., formerly Neoprobe Corporation, is headquartered in Dublin, Ohio. " (5/19/2020)
2. Maxim Group analysts commented, "We are initiating coverage of Buy rating and $2 price target. Navidea is developing an immunodiagnostic platform called Tc99m-tilmanocept (Tc-Til) in rheumatoid arthritis (RA), cardiovascular disease (CVD), Kaposi’s sarcoma, and NASH, and other solid tumors." (7/11/2019)

Has Navidea Biopharmaceuticals been receiving favorable news coverage?

News stories about NAVB stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Navidea Biopharmaceuticals earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutNavidea Biopharmaceuticals.

Who are some of Navidea Biopharmaceuticals' key competitors?

Some companies that are related to Navidea Biopharmaceuticals include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Masimo (MASI). View all competitors.

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Opko Health (OPK), Novavax (NVAX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Rexahn Pharmaceuticals (REXN), FuelCell Energy (FCEL), Agenus (AGEN) and Catalyst Pharmaceuticals (CPRX).

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the following people:

Mr. Jed A. Latkin, CEO, COO, CFO, Sec., Treasurer & Director (Age 45)
Dr. Michael Stanley Rosol Ph.D., Chief Medical Officer
Erika Gibson, Director of Fin. & Admin.
Mr. William J. Regan, Chief Compliance Officer (Age 67)
Ms. Sharon Correia, Sr. Director of Corp. Communications

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $2.57.

How big of a company is Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals has a market capitalization of $55.63 million. Navidea Biopharmaceuticals employs 14 workers across the globe.

What is Navidea Biopharmaceuticals' official website?

The official website for Navidea Biopharmaceuticals is www.navidea.com.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.

This page was last updated on 5/29/2020 by MarketBeat.com Staff